NEW YORK — Theradiag on Monday posted a nearly 7 percent increase in revenues for 2021 on higher sales of its theranostic products.
For the 12-month period ended Dec. 31, Theradiag's revenues were €11.1 million ($12.4 million) compared with revenues of €10.4 million the year before. Theranostics revenues, which include sales of the company's Tracker line of therapeutic drug monitoring tests, were up around 13 percent to €5.8 million from €5.1 million a year earlier. Meantime, in vitro diagnostic sales edged up 1 percent year over year to €5.4 million from €5.3 million.
At the end of 2021, the French company had cash of €7.1 million.
"The solid growth in our revenue objectifies our successful strategic refocus on our theranostics business and the internationalization of our activities in our key geographies," Theradiag CEO Bertrand de Castelnau said in a statement.